Home >> Tag Archives: Fujirebio Diagnostics—

Tag Archives: Fujirebio Diagnostics—

FDA clears Lumipulse G Brahms PCT Assay

June 21, 2018—Fujirebio Diagnostics received FDA clearance of its Lumipulse G Brahms PCT Assay for testing on its Lumipulse G1200 immunoassay platform. The assay is a chemiluminescent enzyme immunoassay for the quantitative determination of procalcitonin in human serum and plasma and offers excellent precision with a CV of ≤4.7 percent. “Serial measurement of procalcitonin levels is a significant innovation for ...

Read More »